Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,818 | 376 | 2,341 |
| Samples | 472 | 117 | 345 |
| Peptides | 421 | 81 | 326 |
Function
RAPH1 · Ras association (RalGDS/AF-6) and pleckstrin homology domains 1
This gene encodes a protein that belongs to the Mig10/Rap1-interacting adaptor molecule/Lamellipodin family of adapter proteins, which function in cell migration. Members of this family contain pleckstrin-homology domains, Ras-association domains, and proline-rich C-termini. The protein encoded by this gene regulates actin dynamics through interaction with Ena/Vasodilator proteins as well as direct binding to filamentous actin to regulate actin network assembly. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2016].
Isoforms & Proteins
10 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000319170 | Q70E73 | 513 | 385 |
| ENST00000374493 | C9K0J5* | 458 | 372 |
| ENST00000630330 | C9K0J5* | 458 | 372 |
| ENST00000453034 | Q70E73-6 | 210 | 177 |
| ENST00000308091 | Q70E73-9 | 209 | 176 |
| ENST00000423104 | Q70E73-7 | 200 | 168 |
| ENST00000439222 | Q70E73-8 | 199 | 168 |
| ENST00000418114 | Q70E73-2 | 191 | 161 |
| ENST00000419464 | Q70E73-5 | 190 | 160 |
| ENST00000457812 | C9J164* | 190 | 160 |
Gene Properties
Recurrent Mutations
All 384 amino-acid changes on canonical ENST00000319170 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RAPH1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RAPH1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 23/612 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 13/210 6% | 37/1899 2% |
| Colorectal Carcinoma | 15/143 10% | 59/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Gastric Carcinoma | 0/74 0% | 28/1809 2% |
| Bladder Carcinoma | 3/58 5% | 11/956 1% |
| Other Solid Cancers | 0/94 0% | 22/1515 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 12/1390 1% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 7/810 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 25/2550 1% |
| Hepatocellular Carcinoma | 2/46 4% | 19/2210 1% |
| Ovarian Carcinoma | 2/109 2% | 8/998 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 13/1592 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Kidney Carcinoma | 3/85 4% | 9/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 10/2534 0% |
| Head and Neck Carcinoma | 2/85 2% | 8/1574 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Other Sarcomas | 1/69 1% | 3/699 0% |
| Glioma | 4/52 8% | 7/2127 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
Mutation Distribution
Where RAPH1 is mutated · all tissues, split by cell line vs tissue
How many mutations in RAPH1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,818 mutations in RAPH1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|